Medindia

X

Reportlinker Adds Blood-Brain Barrier Technologies and Global Markets

Wednesday, May 11, 2011 General News J E 4
Advertisement

NEW YORK, May 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Blood-Brain Barrier Technologies and Global Markets

http://www.reportlinker.com/p0492943/Blood-Brain-Barrier-Technologies-and-Global-Markets.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

REPORT HIGHLIGHTS

*

The global market for blood-brain barrier (BBB) technology for therapeutics amounted to $12.3 million in 2010 and will reach $387 million by 2015, a compound annual growth rate (CAGR) of 99.3%.

*

The most common means of BBB passage or type of technology will be receptor-mediated transport (RMT), meaning crossing the BBB via certain receptors that include the insulin or transferrin receptors. This technology was valued at $12 million in 2010 and is expected to increase at a nearly 99% compound annual growth rate (CAGR) to reach $376 million in 2015.

*

The other technology to emerge as a vehicle for taking a drug across the BBB that otherwise could not cross it is carrier-mediated transport. This sector was valued at $0.2 million in 2010 and is expected to increase at a 121% compound annual growth rate (CAGR) to reach $10.5 million in 2015.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

BCC's goal in conducting this study was to determine the current status of the global therapeutic market for blood-brain barrier (BBB) technologies, including its growth potential over a 5-year period from 2010 to 2015. Our key objective was to present a comprehensive analysis of the current BBB technology and drug development market and its future direction with the aim to first define and classify that technology as it pertains to therapeutics in which the technology enables the therapeutic to directly cross rather than bypass the BBB.

REASONS FOR DOING THIS STUDY

BBB technologies are going to open up a vast untapped potential in the growing central nervous system therapeutic market where today growth is limited by the complexity of this layer in the brain that prevents the passage of many potentially useful molecules/compounds.

This report offers a picture of this technology potential that is on the verge of rapid increase. Therapeutics make up the main area of investment related to this technology; and, therefore, that is this report's focus. BCC has not yet examined the BBB, although the central nervous system has been a consistent focus. As such, this snapshot and study of trending and growth is unique.

SCOPE OF REPORT

The scope of this study encompasses companies that develop technologies to enable the crossing of the BBB and drug development in which a quality of the development is enabling the crossing of the BBB in cases in which passage was previously impossible often due to size. BCC analyzes each technology, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next 5 years. Technological issues, including the latest trends, are discussed.

INTENDED AUDIENCE

In the report, BBB technology is described in terms of what it is and its history in medicine, the types and technology categories, major companies, impact on the pharmaceutical market, applications, current market values, growth potential, and significant trends. This study will be of interest to the biotechnology and pharmaceutical industries and related life science, analytics, drug discovery, and diagnostic test manufacturing companies as well as all those interested or actively working in drug and imaging agent research and investors in all of the above.

METHODOLOGY

BCC presents an analysis of the types of technologies, applications, and therapeutic areas representing financial value in the area of BBB technology in medicine as it relates primarily to drug discovery, development, and commercialization. Estimated values are based on actual aggregate sales for the years discussed. Information, in general, is compiled through a combination of primary and secondary research, including annual reports and interviews with company officials.

INFORMATION SOURCES

BCC's analysis includes the review of more than 50 companies and information from financial and trade publications as well as the U.S. Food and Drug Administration. Included were pharmaceutical and biotechnology companies as well as support companies to them.

CHAPTER ONE: INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THIS STUDY 1

SCOPE OF REPORT 1

INTENDED AUDIENCE 2

METHODOLOGY 2

INFORMATION SOURCES 2

ABOUT THE AUTHOR 2

RELATED BCC REPORTS 2

BCC ONLINE SERVICES 3

DISCLAIMER 3

CHAPTER TWO: EXECUTIVE SUMMARY 4

EXECUTIVE SUMMARY 4

EXECUTIVE SUMMARY (CONTINUED) 5

EXECUTIVE SUMMARY (CONTINUED) 6

EMERGING BBB TECHNOLOGY MARKET 7

EMERGING BBB TECHNOLOGY MARKET (CONTINUED) 8

KEY DRIVERS 9

KEY CHALLENGES 10

MAJOR TRENDS 11

SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR

THERAPEUTICS, THROUGH 2015 ($ MILLIONS) 12

SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR

THERAPEUTICS, THROUGH 2015 ($ MILLIONS) 12

CHAPTER THREE: OVERVIEW 13

TODAY'S PHARMA MARKET 13

FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL

DRUGS, BY REGION, 2009 AND 2015 (PERCENT OF GLOBAL

SALES) 14

FIGURE 2 EMERGING MARKETS' GROWTH IN PHARMACEUTICAL

SALES, 2015 (ESTIMATED $ BILLIONS) 15

TODAY'S PHARMA MARKET (CONTINUED) 16

FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR

THERAPEUTICS, BY REGION, 2015* ($ MILLIONS) 17

BIOLOGICS 18

FIGURE 4 INVESTMENT IN BIOLOGICS AS A PERCENTAGE OF

TOTAL R&D, 2009 (PERCENT OF TOTAL R&D) 18

BIOLOGICS (CONTINUED) 19

GENERICS SIGNAL NEED FOR INNOVATION 20

NEUROFOCUSING IN THE PHARMA INDUSTRY 20

FIGURE 5 CNS REVENUE DISTRIBUTION BY DISEASE TARGET,

2009 ($ BILLIONS) 21

FIGURE 5 (CONTINUED) 22

FIGURE 6 GLOBAL MARKET FOR BBB TECHNOLOGY FOR

THERAPEUTICS, 2015 AND 2017 (NUMBER OF UNITS) 22

FIGURE 6 (CONTINUED) 23

FIGURE 7 GLOBAL MARKET FOR BBB TECHNOLOGY FOR

THERAPEUTICS, BY INDICATION, 2015 AND 2017 (NUMBER OF

UNITS PER INDICATION) 23

FIGURE 7 (CONTINUED) 24

NEUROFOCUSING IN THE PHARMA … (CONTINUED) 25

TABLE 1 TOP PHARMA COMPANIES BY REVENUE, 2009 ($

BILLIONS) 26

EMERGING BBB TECHNOLOGY MARKET 26

BRIEF HISTORY OF BBB 27

BLOOD BRAIN BARRIER DEFINED 28

BBB COMPONENTS 29

FIGURE 8 PARTS OF THE BBB 30

BBB ILLUSTRATED 30

MAIN AREAS OF THE BRAIN 31

FIGURE 9 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO

BLOOD VESSELS 31

TREATING DISEASE AND THE BBB 32

MENINGITIS 33

MULTIPLE SCLEROSIS (MS) 33

ENCEPHALITIS 34

ALZHEIMER'S DISEASE (AD) 34

PARKINSON'S DISEASE (PD) 35

BBB TECHNOLOGY CLASSIFICATION 36

MOST COMMON BBB TECHNOLOGY 37

CHALLENGES WITH THE MOST COMMON TECHNOLOGY

USED 38

TRANSPORT CONSIDERATIONS 39

BYPASSING THE BBB 39

BBB TECHNOLOGY DETAILED 40

CHEMICAL TRANSPORT SYSTEMS 40

BIOLOGICAL CARRIER OR TRANSPORT SYSTEMS 40

PHYSICAL FORCE (ENERGETIC) OPENING THROUGH

SOUND WAVES (TARGETED ULTRASOUND) 41

Physical Force (Energetic) Opening…(Continued) 42

FIGURE 10 METHODS OF CROSSING THE BBB 43

ENHANCING BIOLOGICAL TRANSPORT SYSTEM TECHNIQUES 44

NANOPARTICLES AND LIPOSOMES 44

NANOPARTICLES 44

TABLE 2 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB

TECHNOLOGY 45

Challenges with Nanoparticles 46

Liposomes 47

Liposomes (Continued) 48

PATENTS AND INTELLECTUAL PROTECTION 49

TABLE 3 KEY BBB TECHNOLOGY PATENTS 49

PATENTS AND INTELLECTUAL (CONTINUED) 50

ARMAGEN'S PATENT ESTATE 51

ArmaGen's Patent Estate (Continued) 52

LIFE AFTER PATENTING 53

TABLE 4 SAMPLE OF 2010 FINANCIAL DEALS IN CNS

THERAPEUTICS 54

BBB TECHNOLOGY MARKET: PRESENT AND FUTURE 55

TABLE 5 SAMPLE OF 2010 FINANCIAL DEALS IN BBB

TECHNOLOGY RECEIVED THROUGH PHARMACEUTICAL

COMPANY (ESTIMATED, $ MILLIONS) 55

FIGURE 11 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY

TECHNOLOGY TYPE IN THE DEVELOPMENT PIPELINE, 2010*

(%) 56

FIGURE 12 COMPOSITION OF BBB TECHNOLOGY BY

TECHNOLOGY TYPE IN THE COMMERCIALIZED (THERAPEUTIC

DRUG) MARKET, 2015 (%) 57

BBB TECHNOLOGY MARKET:… (CONTINUED) 58

FIGURE 13 DRUGS IN DEVELOPMENT USING BBB-PASSAGE

TECHNOLOGY, 2010 AND 2015 (NUMBER OF UNITS) 59

TABLE 6 BBB TECHOLOGY COMPANIES AND RESPECTIVE

TECHNOLOGICAL METHODOLOGY 60

TABLE 7 BBB TECHOLOGY COMPANIES AND CORPORATE

PARTNERS/LICENSING DEAL WITH LEAD DISEASE TARGET 61

GENZYME INNOVATES IN-HOUSE 61

DRUG DEVELOPMENT IN THE CNS 62

MULTIPLE MODELS MUST BE USED 63

BBB IS ITS OWN SITE OF INVESTIGATION 63

BBB is its Own Site of Investigation (Continued) 64

UNDERSTANDING INTERACTIONS AND BRAIN AREAS AS

DISTINCT 65

TABLE 8 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING

BBB TECHNOLOGIES 66

TABLE 8 (CONTINUED) 67

WHAT VALUES ARE BEST? 67

TABLE 9 FREQUENT DRUG DEVELOPMENT CHALLENGES AND

THEIR CLINICAL EFFECTS 68

PROMISING RESEARCH 69

PROMISING RESEARCH (CONTINUED) 70

PROMISING RESEARCH (CONTINUED) 71

PROMISING RESEARCH (CONTINUED) 72

PROMISING CNS DRUGS IN THE PIPELINE FOR POTENTIAL

USE WITH BBB TECHNOLOGY 73

BRAIN CANCER 74

TABLE 10 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2015 74

TABLE 10 (CONTINUED) 75

TABLE 10 (CONTINUED) 76

ANXIETY 76

TABLE 11 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH

2015 76

TABLE 11 (CONTINUED) 77

DEMENTIA 77

TABLE 12 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE,

THROUGH 2015 77

TABLE 12 (CONTINUED) 78

PARKINSON'S DISEASE 79

TABLE 13 GLOBAL PIPELINE FOR PARKINSON'S DISEASE,

THROUGH 2015 79

DEPRESSION 79

TABLE 14 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2015 80

TABLE 14 (CONTINUED) 81

PERSONALITY/PSYCHIATRIC DISORDERS 81

TABLE 15 GLOBAL PIPELINE FOR OTHER PSYCHIATRIC

DISORDERS, THROUGH 2015 82

TABLE 15 (CONTINUED) 83

SPINAL CORD INJURY 83

TABLE 16 GLOBAL PIPELINE FOR SPINAL CORD INJURY,

THROUGH 2015 83

ADDICTION DISORDERS 83

TABLE 17 GLOBAL PIPELINE FOR ADDICTION DISORDERS,

THROUGH 2015 84

ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) 84

TABLE 18 GLOBAL PIPELINE FOR ATTENTION DEFICIT

HYPERACTIVITY DISORDER, THROUGH 2015 85

SLEEP DISORDERS 85

TABLE 19 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH

2015 85

TABLE 19 (CONTINUED) 86

CHAPTER FOUR: COMPANY PROFILES 87

ABLYNX NV 87

ABLYNX NV (CONTINUED) 88

ADENIOS, INC 89

ALLON THERAPEUTICS, INC 89

ANGIOCHEM INC 90

ANGIOCHEM INC (CONTINUED) 91

ARMAGEN TECHNOLOGIES, INC 92

ARMAGEN TECHNOLOGIES, INC (CONTINUED) 93

BIOASIS TECHNOLOGIES INC 94

BRAINCELLS INC 95

BRISTOL-MYERS SQUIBB 96

CAPSULUTION PHARMA AG 96

CELLIAL TECHNOLOGIES 97

CYPRESS BIOSCIENCES, INC 97

CENERX BIOPHARMA, INC 98

CEPHALON INC 99

COGNITION PHARMACEUTICALS LLC 99

CYTOS BIOTECHNOLOGY AG 100

DIAMEDICA INC 100

DAINIPPON SUMITOMO PHARMA (DSP) CO, LTD 100

ENVIVO PHARMACEUTICALS, INC 101

ELI LILLY AND COMPANY 102

GENZYME 103

FABRE-KRAMER PHARMACEUTICALS, INC 104

GERON CORPORATION 104

GERON CORPORATION (CONTINUED) 105

INSIGHTEC, LTD 106

INTERNATIONAL BRAIN BARRIERS SOCIETY (IBBS) 107

IN CEREBRO 107

JANSSEN PHARMACEUTICA NV 108

H LUNDBECK A/S 108

H LUNDBECK A/S (CONTINUED) 109

TABLE 20 LUNDBECK'S CNS PIPELINE 110

MEDGENESIS THERAPEUTIX, INC (BIOVAIL LAB) 110

MEDIMMUNE 111

MEDINVENT LLC 111

MITHRIDION, INC 112

NEUROGENETIC PHARMACEUTICALS, INC 113

NEUROVIVE PHARMACEUTICAL AB 113

NSGENE A/S 114

NEUREN PHARMACEUTICALS LTD 115

OPTINOSE 115

OTSUKA AMERICA PHARMACEUTICAL, INC 116

PROTHERAGEN, INC 116

PFIZER 117

TABLE 21 PFIZER'S CNS PIPELINE 118

PHARMACO-CELL COMPANY LTD 118

PHARMIDEX 119

RAPTOR PHARMACEUTICAL CORP 120

ROCHE 121

SHIRE PLC 122

SANERON CCEL THERAPEUTICS, INC 123

SOLVO BIOTECHNOLOGY 123

SPENCER PHARMACEUTICAL 124

SOVICELL GMBH 125

SYNAGEVA BIOPHARMA 126

TARGACEPT, INC 127

TETRAGENEX PHARMACEUTICALS, INC 128

TO-BBB TECHNOLOGIES BV 128

TRANSMOLECULAR INC 129

TTY BIOPHARM 130

UCB 131

VECT-HORUS 131

XENOPORT 132

XIGEN SA 133

To order this report:

Pathology Industry: Blood-Brain Barrier Technologies and Global Markets

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Markets for Emerging Pharmaceuti...
S
Reportlinker Adds Epidemiology: Insomnia